secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-05-15T20:20:37+00:00
Accession:  0001493152-26-023810
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.
- Cash and equivalents $0.7M at March 31, 2026; subsequent $2.0M convertible preferred financing closed April 7.
- Achieved 50% of interim enrollment target in pivotal PF614-301 Phase 3 trial for moderate to severe pain.
- IRB approval secured for Part 3 of PF614-MPAR-102; first peer-reviewed MPAR data published in Journal of Opioid Management.
- Board initiated formal review of strategic alternatives, including partnerships and licensing opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/0001493152-26-023810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer